Immunology Journal Publications
This page includes links to Lilly sponsored clinical trials that have been published in peer reviewed journals over the last 3 years. Each section is sorted by product and may be expanded by each phase. The list of publications below is limited to products that have been approved for use and may contain information about doses, delivery devices, uses, formulations and populations different from product labeling. Clinical decisions should be based on the full safety and efficacy information contained in the product's Full Prescribing Information in the provided link below.
If you have questions about a Lilly study not listed below or would like to request an electronic copy of one of the journal publications on this page, please Contact Lilly services.
Olumiant
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Published Date: January 22, 2019
Baricitinib for systemic lupus erythematosus – Authors' reply
Published Date: February 2, 2019
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Published Date: January 22, 2019
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Published Date: July 21, 2018
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Published Date: March 26, 2022
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
Published Date: February 25, 2020
Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
Published Date: January 22, 2019
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Published Date: September 15, 2018
Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Published Date: September 7, 2018
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis
Published Date: July 29, 2018
Mean cost per number needed to treat of baricitinib versus adalimumab in the treatment of rheumatoid arthritis in Italy>
Published Date: July 27, 2018
No Publication Journals
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
Published Date: September 10, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
Published Date: September 10, 2018
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis
Published Date: April 11, 2018
Efficacious psoriasis treatment improves patients' work productivity
Published Date: April 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis
Published Date: January 9, 2020
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Published Date: December 5, 2019
Achievement of the National Psoriasis Foundation Treatment Targets With Ixekizumab: Pooled Analyses From Four Clinical Studies
Published Date: September 25, 2019
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)
Published Date: November 1, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Published Date: October 20, 2018
A statistical method to convert published response rates into marginal distributions with an example application in psoriasis
Published Date: September 26, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
Published Date: September 10, 2018
Points to consider for analyzing efficacy outcomes in long-term extension clinical trials
Published Date: July 26, 2018
Maintenance of skin clearance with ixekizumab treatment of psoriasis: Three-year results from the UNCOVER-3 study
Published Date: May 25, 2018
Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials
Published Date: September 10, 2018